Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market

Campaign Support:
Eli Lilly and Novo Nordisk, among other pharmaceutical companies, are backing the Obesity Action Coalition's (OAC) Your Weight Matters campaign, which aims to encourage Americans to discuss their weight and health with healthcare providers.

Competitive Market:
Eli Lilly and Novo Nordisk are in a competitive race in the weight loss drug market, with Eli Lilly's Zepbound and Novo Nordisk's Wegovy being key players. Recent quarterly results suggest Eli Lilly is gaining an edge due to better supply management and higher efficacy of Zepbound.

Eli Lilly's Advertising Efforts:
Eli Lilly has launched a new phase of its Get Better campaign, focusing on obesity care and challenging misperceptions about obesity and the use of anti-obesity medications. The campaign includes films like "Shame" and "Big Night," which aim to educate on the appropriate use of GLP-1 drugs and combat obesity stigma.

Market Projections:
Analysts predict that Eli Lilly's Zepbound could surpass Novo Nordisk's Wegovy in sales, with forecasts suggesting Zepbound could reach $27.2 billion in sales by 2030, compared to Wegovy's projected $18.7 billion.

Supply Dynamics:
Eli Lilly's investment in manufacturing capabilities and supply chain improvements has positioned the company well against new entrants in the weight loss and diabetes drug market. Novo Nordisk, on the other hand, faces supply constraints and has revised its full-year profit forecast downward.